A Phase 1/2 Study of the Highly Selective EGFR Inhibitor BLU-701 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Egfr-mutant Non-small Cell Lung Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Pathologically confirmed metastatic Non-Small Cell Lung Cancer with EGFR mutation (exon 19 deletion or L858R) that has had previous treatment with an EGFR tyrosine kinase inhibitor.
    2. Able to swallow an oral medication.
    3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

You may not be eligible for this study if the following are true:

    1. Have disease that is suitable for local therapy administered with curative intent.
    2. Have tumor that harbors EGFR T790M mutation or any additional known driver alterations.
    3. Have central nervous system metastases or spinal cord compression that is associated with progressive neurological symptoms or requires increasing doses of corticosteroids to control the CNS disease.
    4. Have clinically active ongoing interstitial lung disease (ILD) of any etiology, including drug-induced ILD, and radiation pneumonitis within 28 days prior to initiation of study treatment.



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.